|
|
Article: GTC Biotherapeutics Completes Enrollment in European Efficacy Study; Recombinant Human Antithrombin III to be Named ATryn(R).
- Article from:
- PR Newswire
- Article date:
- December 17, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GTC Biotherapeutics, Inc. (Nasdaq: GTCB; "GTC") announced today that enrollment into the efficacy study for recombinant human antithrombin III (rhATIII) has been completed. The results of the efficacy study will be included in a filing requesting marketing authorization in Europe. A total of 14 patients have been enrolled and treated in this study. The efficacy study was designed to assess the ability of rhATIII to prevent blood clots in patients that have a hereditary antithrombin deficiency and are giving birth or undergoing a major surgical procedure. GTC expects to file for marketing authorization in Europe by February 2004. The product will be sold under the name ...